Gold Sponsors

Intech

Steri-Tek

Tecomet


Supporting Organizations

Media

Silver Sponsors

AIP Precision Machining

Carpenter Technology

MedBio

Promimic

Tegra Medical


Bronze Sponsors

Able Electropolishing

PMT

Wednesday, April 27
Location: FedEx Institute of Technology at The University of Memphis
7:00-8:40 a.m. Registration & Continental Breakfast
Sponsored by:
Change width to 240px
8:40-8:45 a.m. Opening Address

Speaker:

    Howard Revitch, ODT/MPO Group Publisher
    Sean Fenske, ODT/MPO Editor-in-Chief
8:45-9:00 a.m. Welcome to Memphis
An introduction of the region serving as the host of the 2021 ODT Forum—Memphis, Tenn.—and an overview of why the area is so important to the orthopedic device manufacturing industry.

Speaker: TBD

9:00-9:45 a.m. The State of Orthopedics: An Industry in Transition
In 2000, how many imagined additive manufacturing, robotics, or payors employing AI systems to manage reimbursements would be playing a role in the orthopedic device industry. Further, that’s to say nothing of a pandemic that cut procedures in half, overnight? Yet, that’s the status of the industry in 2021. The state of our industry is in transition, but the questions of where it’s headed and how fast remain. During this session, Robin Young will review the state of orthopedics now and for upcoming decade.

Speaker: Robin R. Young, CEO, RRY Publications LLC/PearlDiver Technologies Inc.

9:45-10:30 a.m. Biocompatibility Considerations for Orthopedic Devices from the U.S. FDA Perspective
The biological evaluation of medical devices should be in accordance with ISO 10993 series of standards to be acceptable by the U.S. Food and Drug Administration (FDA). Beside general biocompatibility testing considerations applied to all medical devices, each division at FDA has its own risk assessment approach for biocompatibility. In this session, Dr. Kazemzadeh-Narbat will explain the rationales and justifications acceptable for biological risk assessment of orthopedic devices, in accordance with least-burdensome approach, to remove or reduce unnecessary burdens associated with biocompatibility endpoints required by the Agency.

Speaker: Mehdi Kazemzadeh-Narbat, PhD, PMP, CQA; Associate Director, Regulatory Affairs; MCRA LLC

10:30-11:15 a.m. Networking Break
11:15 a.m.-12:15 p.m. Session 4
Description to come

Speaker: TBD

12:15-1:45 p.m. Networking Luncheon
1:45-2:30 p.m. Session 5
Description to come

Speaker: TBD

2:30-3:15 p.m. Session 6
Description to come

Speaker: TBD

3:15-4:00 p.m. Networking Break
4:00-5:00 p.m. Session 7
Description to come

Speaker: TBD

5:00 p.m. End of Conference
Wifi provided courtesy of Change width to 240px
* All session times, speakers, and content are subject to change.